For instance, it is widely known that aberrant epidermal growth factor receptor (EGFR) signaling lead to various oncogenic phenotypes [56] and previous PGx invetigations have shown that the EGFR gene mutation status was associated with EGFR-targeted agents efficacy such as Erlotinib’s (rank 2) in the case of non-small cell lung cancer (NSCLC) [56, 57]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.